Last46.16 +1.79 (+4.03%)
41.1 - 93.94
52 Week Range
Technical Indicators (Daily)
Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN)
— Companies to advance clinical development of DNL593 as a brain-penetrant progranulin replacement therapy for frontotemporal dementia-granulin (FTD-GRN) — SOUTH SAN FRANCISCO, Calif., Nov. 17, 20...
Baron Funds, an asset management firm, published its “Baron Health Care Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. A return of 1.18% was delivered by the ...
Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement....
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -35.29% and -78.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro...
Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.